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A B S T R A C T
Comparative oncology is defined as the discipline that integrates naturally occurring cancers seen in veterinary
medicine, into more general studies of cancer biology and therapy in humans, including the study of cancer-
pathogenesis and new cancer treatments. While experimental studies in mice and rodents offer several ad-
vantages, including a wealth of genetic information, reduced variation and short generation intervals, their
relevance in cancer biology is somewhat limited. Toward this end, as the biomedical research community works
to make the promise of precision medicine a reality, more efficient animal cohort studies are critical. Like
humans, companion animals such as cats and dogs living in family homes, are exposed to environmental factors
that may influence the development of disease. Furthermore, it has been shown that the basic biochemical and
physiological processes of companion animals more closely resemble humans compared to rodents. Research has
demonstrated that female domestic cats (Felis catus) may represent a comparative model for investigation of
mammary carcinogenesis, and in particular, Triple Negative Breast Cancer (TNBC). TNBC is a subtype of breast
cancer that typically lacks the expression of the oestrogen receptor (ER), progesterone receptor (PR), and does
not overexpress the human epidermal growth factor receptor 2 (HER2).
An exciting and rapidly expanding area in cancer biology is the study of exosomes. Exosomes are nano-
particles released from cells and have been found in biological fluids of humans, domestic cats and dogs. In
addition to their role as biomarkers, exosomes are implicated in the pathogenesis of certain diseases, including
cancer. This review explores the current understanding of exosome biology in human TNBC, and of the potential
benefits of comparative research in naturally-occurring mammary tumours in companion animals.
1. Triple Negative Breast cancer (TNBC)
1.1. What is Triple Negative Breast Cancer (TNBC)
Triple negative breast cancer (TNBC) is a subtype of breast cancer
that typically lacks the expression of the oestrogen receptor (ER), pro-
gesterone receptor (PR), and does not overexpress the Human
Epidermal Growth Factor Receptor 2 (HER2). Consequently, treatments
that have been developed to target these receptors are not effective in
this form of breast cancer. TNBC accounts for between 10 and 15% of
all breast cancer subtypes [35]. TNBC shares some molecular and bio-
logical characteristics with so called ‘basal like” breast cancer, but these
tumour subtypes are not identical [35]. In general, TNBC is an
aggressive form of cancer with a higher relapse rate and metastatic
potential, than other types of breast cancer [2,101], although increas-
ingly, low grade, more indolent forms, are recognised [40]. TNBC most
commonly metastasises to the lung, liver and brain [101]. Metastasis in
breast cancer is a multistep process involving dynamic interactions
between tumour and stromal cells, and the host immune micro-
environment, ultimately resulting in the detachment and movement of
primary tumour cells to secondary sites [3]. Despite best efforts to
develop personalised therapies for women with TNBC, fewer than 30%
of patients with metastatic TNBC are alive at five years following di-
agnosis, and almost all unfortunately will die as a result of their cancer
[2].
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1.2. Genomic TNBC Classification
Understanding the complexity of TNBC is a focus of many research
efforts, including the Cancer Genome. Several emerging research efforts
have aimed to increase the understanding of the complexity of TNBC
including the Cancer Genome Atlas Research Network, who have ana-
lysed primary breast cancers using platforms such as DNA methylation,
exon sequencing and reverse-phase protein arrays (Cancer Genome
Atlas [21]). This work has shown that the most frequent loss-of-function
alterations in TNBC, involves genes associated with DNA damage re-
pair, including loss of the tumour suppressor genes TP53, RB1 and
BRCA1 functions. Aberrant activity of PI3K signalling pathways, has
also been frequently reported (Cancer Genome Atlas Research [21]).
Further information to support the heterogeneity of TNBC comes from a
study by Shah et al. [86], who sequenced and analysed TNBCs from 100
women at the time of diagnosis. High rates of somatic mutations in the
TP53 gene were found; mutations that result in an altered p53 protein
that is less able to control cell proliferation. However, 12% of tumours
did not have any recorded somatic mutations in these so-called driver
genes [86].
Gene expression analyses have demonstrated the diversity of in-
trinsic subtypes of TNBC, and have partially helped to decipher the
complexity of TNBC heterogeneity. Approximately 70% of TNBC cells
are reported to be “basal-like” [79]. Similarly, not all “basal-like” tu-
mours are “triple negative” by immunohistochemistry (IHC) [79]. In
other words, although “triple-negative” and “basal-like” breast cancers
share similar morphological features, these terms are not interchange-
able. The term triple negative is formed on the basis of clinical assays
for ER, PR and HER2, whereas the term “basal-like” is based on mi-
croarray gene expression analyses. The majority of metaplastic and
medullary-like cancers which are typically TNBCs, also show a “basal-
like” phenotype, which is rarely found in other types of breast cancer
[13]. Significant efforts in genome-wide gene expression profiling
analyses have improved our understanding of the diversity of TNBC,
with at least six different subtypes being described by Lehmann et al.
[58] namely basal-like 1, basal-like 2, immunomodulatory, mesench-
ymal, mesenchymal stem-like and luminal androgen receptor positive.
These subtypes have been reproduced and pharmacologically targeted
in breast cancer cell lines, as evidence that they can potentially inform
therapy selection. However, for patients, very little is known about the
factors driving these distinct molecular events or how to treat them
effectively using targeted therapies. Therefore, it has been argued that
the relevance of classifying TNBC in this way is somewhat trivial.
However, in reality, this classification is a significant advance and will
form the basis of future treatments [8,58]. More extensive research is
needed to clarify the potential impact of this classification strategy on
TNBC treatment decisions.
1.3. Histology
According to a study of 19,900 TNBC patients [60], most patients
with TNBC have a histological diagnosis of invasive ductal carcinoma,
no special type [23] (Fig. 1). Other histological subtypes with a triple
negative profile include carcinoma with medullary features, meta-
plastic carcinoma, apocrine carcinoma, pleomorphic invasive lobular
carcinoma, adenoid cystic carcinoma and microglandular carcinoma
[16,31]. The histological heterogeneity is reflected in clinical outcome,
including survival rates [60].
In general, “Triple Negative” and “basal-like” tumours are char-
acterised by aggressive histological features including high tumour
grade, a high degree of mitotic activity and necrosis. Tumours are
frequently large and tumour infiltrating lymphocytes (TILs) may be
prominent [9,53]. In addition, a further contribution to the hetero-
geneity of TNBC, is that low grade TNBCs are now recognised, for ex-
ample adenoid cystic carcinoma and secretory carcinoma [40].
At the immunohistochemical (IHC) level, “basal-like” breast cancers
are characterised by the expression of proteins normally found in the
basal/myoepithelial cells of the normal breast, including high mole-
cular weight (basal) cytokeratins (CK5/6, CK14 and CK17) (Fig. 2).
Therefore, the term “basal-like” stems from the similarity between the
IHC and molecular profile of these tumours, and that of basal/myoe-
pithelial cells of the normal breast [77]. This “basal-like” subtype is
typically associated with a poor clinical outcome, most likely reflecting
its high proliferative capacity, high grade, and the lack of targeted
systemic therapy, since “basal-like” tumours express a low level of ER
and do not overexpress HER2 [88]. The poor prognosis associated with
the “basal-like” phenotype of breast cancer may be due to lack of ER
expression and cyclin E positivity, rather than to expression of CK5/6 or
CK17 expression [78].
1.4. Treatments: Surgery and Chemotherapy
The mainstay treatment for patients with TNBC, remains cytotoxic
chemotherapy, such as anthracycline and taxane-based chemotherapy.
Specifically, in addition to locoregional treatment, the standard care for
TNBC is combination chemotherapy, most usually and traditionally,
doxorubicin in combination with carboplatin or cyclophosphamide
[55]. Thus far, no appropriate molecular targets have been identified
for patients with TNBC, and they therefore do not benefit from targeted
therapies such as endocrine therapy that are fuelling the personalised
medicine era [37]. For the most part, the lack of targeted therapies
available for TNBC is due to the innate heterogeneity of TNBC itself
[59].
Neoadjuvant chemotherapy has been historically used to downstage
non-resectable tumours for better loco-regional control and higher
conservative surgery rate [80]. After receiving neoadjuvant che-
motherapy, about 30% of patients with TNBC present with a patholo-
gical complete response (pCR). Pathological complete response is de-
fined as the absence of residual invasive cancer in the resected breast
specimen and all regional lymph nodes sampled following completion
of neoadjuvant chemotherapy [80]. After neoadjuvant therapy,
achieving a pCR improves the outcome for TNBC patients to the point
that their disease free survival and overall survival, are similar to pa-
tients with less aggressive, non-triple negative tumours [29]. However,
TNBC patients with residual disease following neoadjuvant and ad-
juvant chemotherapy, typically have a worse survival and prognosis
than those non-triple negative presentations. Some are of the opinion,
that pCR may therefore be considered a potential surrogate marker for
survival in TNBC [22,29].
Breast-conserving surgery (BCS) including radiotherapy (RT), has
been found to provide at least equivalent prognosis to mastectomy in
early stage breast cancer [93]. However, studies on women with TNBC
are relatively scarce [93], with the outcomes associated with BCS and
mastectomy remaining controversial. Specifically, a study by Chen et al.
[26], used the Surveillance, Epidemiology, and End Results (SEER)
database, to enrol 11,514 female TNBC cases who were diagnosed
during the period of 2010–2013. Patients were subdivided into two
groups; those who received BCS and RT, and those that received a
mastectomy. When the patients were stratified according to age, his-
tology grade, TNM stage, tumour size and lymph node status, the ma-
jority of patients who received BCS together with radiotherapy, de-
monstrated a better survival (both overall survival and breast cancer
survival), compared to the mastectomy group alone, therefore pro-
viding evidence for surgeons in favour of BCS for women with TNBC.
Radiation therapy has been shown to be useful for the management
of TNBC. The indications for radiotherapy for breast cancer are mainly
based on TNM staging. Radiation therapy of the chest wall after mas-
tectomy, and the regional area, as well as after breast conserving
therapy is a relatively common treatment approach for TNBC [98]. A
cohort study by Abdulkarim et al. [1], involving 768 patients with early
stage TNBC, investigated whether postoperative radiotherapy can
minimise the risk of local recurrence of TNBC. This study showed that
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Fig. 1. Haematoxylin and eosin (h & e) stained
tumour sections comparing the histological fea-
tures of a human high-grade invasive breast
carcinoma (a, b, c) compared to a feline high
grade mammary adenocarcinoma (d, e, f). 1a
demonstrates the circumscribed outline of the carci-
noma and some lymphocytes at the periphery of the
tumour. 1b shows the solid arrangement of the tu-
mour cells with intervening prominent lymphocytes
(see arrow). 1c shows marked nuclear pleomorphism
(yellow arrow) and abnormal mitotic figures (blue
arrow).1d and 1e, show prominent lymphocytes at
the periphery of the tumour. 1f demonstrates marked
nuclear pleomorphism (yellow arrow) and abnormal
mitotic activity (blue arrow). 1a, 1b and 1c have
scale bars representing 100µm diameter (1a and 1b)
and 50µm (1c). 1d, 1e and 1f have scale bars re-
presenting 100 µm, 50 µm and 25 µm
respectively. Feline images were taken from a 5-year-
old female neutered domestic short haired cat, while
human images were taken from an adult female with
a diagnosis of TNBC.
Fig. 2. Immunohistochemical staining of cytoker-
atin 5/ 6 showing “basal-like” positive signatures in
both human (a) and feline mammary adenocarci-
noma (c) with paired haematoxylin & eosin stained
sections (b & d). 2a represents positive staining for
cytokeratin 5/6 in human breast cancer with matched
haematoxylin & eosin stained section (2b). 2c represents
positive staining for cytokeratin 5/6 of a feline high
grade mammary adenocarcinoma (FMA) with matched
haematoxylin & eosin stained section. This feline also
had multiple lymph node metastases and had marked
desmoplasia both within the mammary gland tumour
and within the lymph nodes. Size bars represent 50µm
for 2a and 2b. Size bars represent 25 µm for 2c and 2d.
Feline images were taken from a 14 year old female
neutered domestic short haired cat, while human images
were taken from an adult female with a diagnosis of
TNBC.
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women treated with radiation therapy had significantly increased sur-
vival when compared to those women who did not receive radiation
therapy, highlighting the importance of radiotherapy within the TNBC
treatment regimen [1]. In addition, in relation to radiotherapy post-
mastectomy, it has been shown that radiotherapy can improve the
outcome for TNBC. A prospective randomised trial by Wang et al. [96]
examined the postoperative treatment regimen of women following
radical mastectomy, demonstrating that the 5-year overall survival rate
of patients treated with radiotherapy, was 11.6% higher than that of the
non-radiotherapy group, supporting the post-operative radiation for
women with TNBC [96].
1.5. Clinical Trials and the Unmet Clinical Need in TNBC
Patients diagnosed with TNBC represent a substantial unmet clinical
need. The sheer characterisation of TNBC as ER, PR and HER2 negative,
represents one of the most prevalent clinical challenges for these pa-
tients, because they cannot be treated with endocrine therapies or other
readily available targeted therapies (for example Herceptin/
Trastuzumab). The majority of clinical trials [28] in TNBC, are focused
on varying combinations of cytotoxic chemotherapy in order to max-
imise the disease free survival period [48]. Additionally, in comparison
to other breast cancers, TNBC has been associated with an increased
metastatic potential, with a shorter median time to relapse and death.
One of the most important goals in TNBC research is the identification
of markers to predict the location of metastasis and to predict treatment
response [48].
Based on this profound unmet clinical need, Synnott et al. [91] have
suggested that as the tumour suppressor gene TP53 is mutated in ap-
proximately 80% of TNBC cases [75], this may constitute a potential
biomarker for TNBC patients. COTI-2 is a third generation thiosemi-
carbazone derivative, which acts by reactivating mutant p53 to a
wildtype form. It has been developed for high efficacy and low toxicity
as a potential targeted therapy for TNBC patients by acting on mutated
p53. However, it is also capable of acting “independently of p53, by in-
hibition of the mTOR pathway and activation of AMPK” [61]. COTI-2 is
currently showing great potential as it undergoes phase I clinical trials
for the treatment of gynaecological and other cancers [46]. Synnott
et al. [91] showed the anti-proliferative effects of COTI-2 in response to
mutant p53 in TNBC, and also supported previous reports, demon-
strating that, in addition to inhibiting the growth of mutant p53 cell
lines, COTI-2 also inhibited the proliferation of p53 wildtype cells
[18,32]. This may be as a direct result of mTOR pathway inhibition
[91]. Interestingly, when COTI-2 was combined with traditional cyto-
toxic chemotherapy, such as doxorubicin or carboplatin, synergistic
growth inhibition of mutant p53 cell lines was observed. While only at
an early clinical trial phase, COTI-2 represents one of the first and only
targeted treatments for TNBC patients [91].
2. Comparative Oncology
2.1. The Need for Alternatives to Mouse Models in Cancer Research
Despite an improved understanding of cancer molecular biology,
immune landscapes and advances in cytotoxic, biologic, and im-
munologic anti-cancer therapeutics, cancer remains a leading cause of
death in both animals and humans worldwide. While experimental
studies in mice and rodents offer several advantages, including a wealth
of genetic information, reduced variation, short generation intervals,
ease of maintenance and handling at a more affordable cost, the lack of
genetic diversity, shared environments, lifespan and naturally-occur-
ring tumours, constitute the importance of companion animal patient
cohorts. According to a report published by the National Academies of
Sciences in 2015, a mere 11% of anti-neoplastic therapies that de-
monstrate efficacy in murine models have been approved for human
use, representing a high attrition rate for emerging therapies as well as
a need for more advanced and more relevant animal studies [42]. It is
therefore clear that there are several weaknesses associated with the
use of laboratory animals as models in cancer research. For example,
humans are 3000 times larger than mice, they also live up to 50 times
longer undergoing about 105 more cell divisions in a single lifetime
[81]. Furthermore, it has also been proven that the microenvironment
of tumours in genetically engineered mouse models is significantly
different in a number of ways to that of human cancers. This differing
microenvironment along with the genetically bred homozygosity of
mice, often results in overly favourable predictive responses to che-
motherapy, radiation therapy and immunotherapy [47].
Although murine studies have been invaluable, and will remain a
critical first step of preclinical research for cancer biology and ther-
apeutics, their shortcomings and the need for additional, be it more
reliable animal models are being increasingly recognised. With better
models/cohorts that recapitulate human conditions emerging, it is
possible that fewer failures may be observed in human clinical trials. In
addition, better models may also shorten the pre-clinical and clinical
trial phases [84]. Toward this end, as the biomedical research com-
munity works to make the promise of precision medicine a reality,
novel animal models of naturally-occurring cancer may play a crucial
role in bridging the gap between fundamental diagnostics, therapeutics
and human clinical trials.
2.2. Comparative Oncology: A Definition
The term “Comparative Oncology” has been defined as the discipline
that integrates the naturally occurring cancers seen in veterinary pa-
tients into more general studies of cancer biology and therapy, in-
cluding the study of cancer-pathogenesis and new treatments [92]. In
1896 during his valedictory address at McGill University, Wesley Mills
recognised the importance of the discipline stating that “Comparative
medicine is the medicine of the future, and the sooner it is realised, the better,
for man and beast” [69]. More recently, Garden et al. [39] described the
“far-reaching benefit of comparative oncology” for both animals and
humans with a diagnosis of cancer.
Although a number of veterinary species including the cat, horse,
pig and ferret, have demonstrated comparative potential, the majority
of research efforts thus far have focused on the dog [102]This focus is
due to the strong anatomical and physiological similarity between dogs
and humans. While extremely beneficial for both cohorts, a shift in
focus to other animals such as cats and pigs has the potential to benefit
other disease areas. Cancer is a major cause of morbidity and mortality
in animals [4], with reports indicating that cancer kills 40–50% of ca-
nines over the age of 10 years [4,94].
2.3. Advantages of Studying Spontaneously Occurring Cancer in
Companion Animals
Precision medicine is simply defined as the right treatment for the
right patient, at the right time. This therefore demands highly relevant
translational models to recapitulate disease [84]. To date, cancer re-
search has been limited by the lack of genotypically and anatomically
relevant non-rodent animal studies. In theory, an ideal animal for
comparative oncology should (i) mimic disease on a molecular basis,
(ii) derive from a relevant tissue type, (iii) be reliable and predictable,
(iv) manifest survival differences, (v) allow for accurate treatment as-
sessment, (vi) be readily imaged and (vii) occur in a similar back-
ground to the human disease [6]. Investigating spontaneously occurring
cancers in companion animals is an underutilised clinical resource that
can play a crucial role in bridging the gap between fundamental diag-
nostics and human clinical trials. When compared to murine/rodent
models, there are numerous advantages of spontaneously occurring
disease in animal studies that increase their clinical fidelity, making
them a potentially useful tool in cancer research and the precision
medicine era. Spontaneous disease in companion animals such as cats
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or dogs, are capable of closely recapitulating human cancer and asso-
ciated comorbidities. This therefore, potentially provides an avenue for
the analysis of both human and animal cancers [84]. The natural oc-
currence and history of cancer in animals and humans permits the rapid
study of DNA damage and epigenetic alterations that accumulate over
time underpinning resultant tumour development [43]. Some animals
are said to exhibit a “compressed pathology”, whereby cancer progres-
sion, development of metastasis and response to chemotherapy is seen
at a more rapid rate, compared to humans with a similar cancer type.
As humans and animals share many diseases, it is not surprising that
they often share similar genetic mutations. A commonly used example
of this similarity is canine X-linked haemophilia A, which is caused by a
gene inversion in factor VIII, the same as in humans [62]. Despite large
genetic variations due to outbreeding of some animal species, selective
breeding has led to an increased prevalence of particular cancers in
dogs and cats. The study of cancer genomics in animals offers the op-
portunity to identify new gene associations currently not recognised in
human disease which could translate into the identification of novel
targeted therapies. Similar to humans, cats and dogs living in family
homes as pets are also exposed to the same lifestyle risk factors and
external environmental factors such as toxins and carcinogens. Similar
to humans, these factors often influence the development of certain
diseases. Passive smoking has been shown to increase the risk of the
development of malignant lymphoma [11] and oral squamous cell
carcinoma [12] in cats, while obesity increases the risk of development
of diabetes mellitus in domestic cats [25]. Similarities are also noted in
therapeutics, where the efficacy of certain chemotherapeutic agents
and/or other hormonal therapies is similar in animals as in man [76].
Specifically, as an example, CHOP-based (cyclophosphamide, hydro-
xydaunorubicin, oncovin, prednisone) protocols are the mainstay of
treatment for certain lymphomas in man and in dogs, and result in si-
milar response and remission rates [136] Importantly, the hetero-
geneity of diseases seen in veterinary medicine closely models that of
human patients. Specifically, it has been shown by Parker et al. [76],
that the basic biochemical and physiological processes of dogs more
closely resembles human beings compared to rodents [76].
2.4. Canine Breast Cancer
Canine cancer is a serious clinical issue in veterinary medicine. It is
estimated that one in four dogs greater than two years of age will die
from some sort of cancer, with certain breeds such as Bernese mountain
dog, Irish wolfhound, flat-coated retriever and Saint Bernard, over re-
presented in terms of cancer incidence and mortality [33,73,92]. In-
terestingly, the risk of tumour development increases depending on the
time of ovariohysterectomy (spaying/neutering) [10]. According to
Beauvais, Cardwell and Brodbelt, if a dog is spayed before her first
ovarian cycle, the risk of tumour development is 0.5%. However, if
spayed just after or any time later, the risk increases to 8%. Approxi-
mately 50% of canine mammary tumours are malignant [10].
Mammary tumours are the second most common neoplasia in dogs,
typically occurring in females between the ages of 8–10 years [87].
Canine Mammary Tumours (CMT) are highly similar to human breast
cancers at the clinical level [121]. Therefore, it is not surprising that
human biomarkers of breast cancer are also detectable in cases of CMT
[121] [52]. The incidence of cancer in dogs has increased steadily [73].
This may be due to an increase in the population of dogs at risk, and/or
the awareness and interest of pet owners. The improved general health
of pets as a result of vaccines, better nutrition and better, more acces-
sible veterinary care are allowing dogs to live longer, which may indeed
be contributing to the increased incidence of age-related diseases such
as cancer observed in these patients [73]. Thus far, the only successful
treatment for CMTs is surgery, which consists of the removal of the
altered glands and local lymph nodes [54]. In some cases of malignant
CMT, chemotherapy and radiotherapy are administered. However, this
is costly and there is limited information about the efficacy of the
treatment [24]. The clinical need for biomarkers for early detection,
treatment response and disease progression is therefore a research
priority in this area [52].
3. Feline Mammary Adenocarcinoma (FMA)
3.1. What is FMA?
Feline mammary tumours predominantly present as adenocarci-
nomas [45]. Feline mammary adenocarcinoma (FMA) is the third most
common tumour in cats, following lymphoid and cutaneous neoplasms
[95, [113]]. The majority of FMAs are malignant [45]. and the the ratio
of benign to malignant tumour presentations has been estimated to be
between 4:1 and 9:1 [45]. FMA is a highly aggressive, hormone re-
ceptor negative cancer, with comparative pathology and poor prognosis
similar to human TNBC. Domestic animals have a shorter overall life-
span and often show more rapid progression of cancer when compared
to humans, thus allowing for treatment response comparisons to hu-
mans which is of interest not only to veterinary clinicians, medics and
researchers but also to owners who often demand the use of the most
advanced therapeutic tools for their pets [102]. However, interestingly,
few studies have evaluated FMA’s as a potential comparative cohort of
patients to study human TNBC [114].
Mammary tumours in domestic cats are relatively common, occur-
ring in approximately 31.8 and 20.4 in 10,000 intact cats and ovar-
iohysterectomised cats respectively [7]. FMA typically occurs in older
cats between the ages of 10 and 14 years, with the Siamese breed of cats
having a higher risk even at a younger age [135]. In an early study of
179 malignant feline mammary tumours, Weijer, Head, Misdorp and
Hampe [134], reported that the mean age at first detection, was 10.8
years with the average survival time following diagnosis being 12.3
months. Additionally, they reported that of the 179 studied, 120 pre-
sented with metastases, with most cancer progressing to the lymph
nodes, lungs, pleura and liver. This finding of a predominance of ma-
lignancy in relation to mammary tumours in cats has been echoed by a
number of studies and investigations [15]; [114]. There is abundant
evidence to show that FMA shows an age associated, histopathology,
biologic behaviour and a pattern of metastasis similar to human breast
cancer [63] [134]. Hahn, Bravo and Avenell [113], have stated that
naturally occurring tumours develop as frequently in animals as in man.
Additionally, FMA also demonstrates a marked heterogeneity of mole-
cular signatures between primary and metastatic lesions [127]. How-
ever FMA progresses at a much more rapid rate in our domestic pets
when compared to human breast cancer. Reports of overexpression and
amplification of cyclin A, and p53 nuclear accumulation, also indicate a
similar molecular tumourigenesis [71].
3.2. FMA Histology and Prognostic/Predictive Indicators
In situ and invasive variants of FMA have been described. Prognostic
parameters in FMAs have been characterised, including tumour size,
histological grade, lymph node involvement and expression of pro-
liferation markers [30] (Fig. 1)(Fig. 2). An example of a case of a his-
tologically high-grade feline mammary adenocarcinoma from a 5 year
old female neutered domestic short haired cat is shown in figure 1. A
study by Burrai et al.,[17] examined tumours from 203 female cats of
varying breeds, showing that the majority of FMAs were ER negative,
PR negative and did not overexpress HER2 [17]. Cell proliferation as
assessed by expression of Ki67 has been found to be higher in FMAs
than benign tumours [30] Ki67 expression was also found to corre-
sponds to the histological grade with higher grade tumours showing
higher expression (Dias Pererira, Cavalheira and Gärtner, [30] con-
cluded that prognosis of FMAs could potentially be assessed using the
size of tumours, histological grading, lymph node involvement and
expression of proliferative markers. Additionally, a study by Soares
et al., [129] investigated the use of Ki67 as a prognostic indicator in
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felines. 96 female felines with mammary carcinoma were examined. It
was shown that a high Ki67 index was capable of predicting shorter OS,
larger tumour size, more malignant tumours, presence of necrotic areas
and low ER expression. In addition to its use as a prognostic biomarker,
it was also proposed by Soares et al., that 14% Ki67 staining may be
used as the optimal cut off for distinguishing high from low malignant
potential and identifying high risk of disease progression. Despite these
clear advances, further research is necessary to confirm the role of Ki-67
as a single marker of prognosis [30][114][129].Additionally, a number
of histological grading systems commonly used in the human clinics
have been applied to FMA, with the adapted Elston and Ellis scoring
system [36] most commonly used with varying results. A relatively
large study of 92 spontaneous invasive carcinomas of the mammary
gland showed that histological grade using the Elston and Ellis grading
system correlated with both overall survival and disease free survival
[85]. Mills et al., [70] assessed the prognostic value of histological
grading on 108 feline mammary tumours. They found Elston and Ellis
grading to be a poor indicator of prognosis for feline patients and a poor
indicator of overall survival. All studies agree that histologic grading of
feline mammary carcinomas has the potential to significantly improve
routine diagnostic evaluation and prognostication. Wiese et al., ([97])
investigated histological features including immunohistochemical eva-
luation of ER, PR, HER, CK5/6 and EGFR in order to investigate the
growth pattern, tumour grade, mitotic index, the presence of necrosis,
microcalcification, and a lymphocytic reaction associated with tumours
in 24 cats with FMA. Fourteen out of 24 cats (58.3%) presented as triple
negative, while 11 of those 14 (79%) were identified as “basal-like”.
They also showed FMAs, to be (i) aggressive tumours with a potential to
metastasise and (ii) display morphological features similar to human
breast cancer, suggesting that client owned cats may be a suitable
spontaneous animal cohort for studying novel therapeutic approaches
against human “basal-like” TNBC [97]. Finally, the study was supportive
of the use of the Elston and Ellis grading system as a prognostic in-
dicator; a grading system commonly used in human breast cancer [97].
An example of a case of feline ‘basal -like’ mammary adenocarcinoma
showing positivity for CK5/6 from a 14 year old female neutered do-
mestic short haired cat is shown in Figure 2 in comparison to a similar
tumour in humans.
While proliferative markers, such as Ki67 and AgNOR, have been
used as predictors of survival rates, the prognostic value of the ex-
pression of hormone receptors and HER2 is more controversial. Similar
to human TNBC, the majority of feline tumours are ER negative [17],
PR negative [44,17] and lack HER2 overexpression [124]. Millanta
et al. [67] have shown that ER and PR expression cannot be considered
definitively prognostic in cases of feline mammary neoplasia. The
conflicting findings of most studies regarding the prognostic values of
these receptors, is likely due to the low numbers of cases assessed
[103]. As discussed previously, ‘basal-like’ breast cancer is associated
with immunohistochemical (IHC) positivity for the basal markers CK5/
6, CK17, CK14 and EGFR, while ‘triple negative’ breast cancer is de-
fined by negative expression of ER, PR and lack of overexpression of
HER2 (Fig. 2). Wiese et al. [97] evaluated FMAs according to human
TNBC IHC staining of ER, PR and HER2 as well as cytokeratin CK5/6
and EGFR and found that 79% of FMAs were negative for ER, PR and
HER2 and exhibited a “basal-like” subtype. Soares et al., [127] used the
St. Gallen International expert consensus panel to examine 61 felines
with a diagnosis of mammary caner. Gene expression profiles were
compared to local regional and distant metastasis. It was shown that
triple negative “basal-like” mammary cancers showed lowest survival
and shortest DFS. In addition, the majority of metastasis were triple
negative with 50.7% of metastasis expressing CK5/6. A later study by
Soares et al., published in 2016 further characterised the clinical and
pathological features of feline mammary carcinomas and also supported
the proposed heterogeneity of feline mammary carcinomas.[128] This
research also eluded to the similarities between clinicopathological
characterisation of both human and feline breast cancer. However
importantly, Soares et al., commented on the difficulty faced when
comparing clinicopathological results from felines to humans. Felines
commonly develop multiple masses within the same mammary chain
which can make interpretation of results more difficult. This is ex-
tremely rare in woman with “basal-like” breast cancers. As work in the
interface between Veterinary Medicine and Clinical Medicine in hu-
mans progress, it is clear that spontaneous tumours in companion an-
imals, offer the potential to study a very useful translational cohort
[108].
3.3. Treatments: Surgery and Chemotherapy
Surgery remains the treatment of choice for feline mammary neo-
plasms, and may be used on its own or in combination with other
modes of cancer therapy, such as chemotherapy [66]. In order to
minimise the risk of recurrence, chain mastectomy is the preferred
treatment plan, regardless of tumour size. A study by Gemignani et al.,
[110] examined 107 client owned cats, who underwent surgery for the
treatment of a feline mammary neoplasm. Their study examined the
incidence of disease progression and disease specific death identifying
significant risk factors for disease progression including unilateral
mastectomy, tumour ulceration and lymph node metastasis. Significant
risk factors for disease specific death, included lymph node metastasis
and development of distant or regional metastasis. Finally, their study
also showed that chemotherapy treatment alone, was also associated
with a significantly decreased risk of disease-specific death [110].
While results from this study support bilateral mastectomy and che-
motherapy to improve progression free survival time, a study by
Campos et al., [20] showed little or no increase in overall survival (OS)
of patients who received chemotherapy together with surgery, com-
pared to surgery alone [20]. Like humans, early intervention and
treatment is extremely important for FMAs, with few effective therapies
available for advanced disease.
Chemotherapy, although not the most adopted treatment for FMA,
follows similar pathways to human TNBC. Doxorubicin is available as a
single agent or in combination with cyclophosphamide [65,[128,129].
Similarly, carboplatin may be administered as a single agent or in
combination with doxorubicin [20]. Despite the advanced treatment
regimen, additional clinical trials are required to assess effective che-
motherapeutic doses and combinations. A study was carried out by
Campos et al. [20], to compare OS periods of felines subjected to
varying treatment protocols including surgery alone and surgery to-
gether with adjuvant chemotherapy. Despite the fact that carboplatin is
indicated for the treatment of both canine and feline malignant mam-
mary gland neoplasms [56], no significant statistical difference in OS
was observed between domestic cats who received surgery alone,
compared to patients who received carboplatin in addition to surgery.
Similarly, a study by McNeill et al. [65] tested whether doxorubicin-
based chemotherapy improved the outcome for feline mammary car-
cinomas when compared to surgery alone. Of the 73 cats included in the
study, 37 received surgery alone, while 36 received surgery followed by
chemotherapy. Outcomes demonstrated that there was no statistically
significant difference in survival of the felines who were treated with
adjuvant doxorubicin following surgery [65].In an attempt to improve
clinical management of feline mammary carcinoma, a study by Ferreira
et al., [107]investigated the potential of TOP2α as a biomarker. It was
shown that TOP2α gene aberrations are capable of predicting response
to anthracycline based chemotherapy and amplification of TOP2α was
associated with a better outcome for the feline patient cohort [107].
These studies clearly show a similarity between human and feline re-
sponses to treatment regimens with poor OS outcomes for both, using
these chemotherapies and also highlight how research in the com-
parative medicine area has the potential to improve the overall survival
of felines and TNBC patients.
COX-2 has also been investigated in FMAs. As is the case with
human breast cancer, overexpression of COX-2 correlates with the
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aggressive and invasive potential of tumour cells, playing a role in
carcinogenesis. In agreement with studies carried out on human breast
tissues, a study by Millanta et al. [68] showed that 96% of FMAs ex-
pressed COX-2, in comparison to the normal mammary tissue, which
demonstrated the absence of COX-2 expression. Studies investigating
the use of COX-2 inhibitors have had limited success. A study by Bor-
rego et al. [14] evaluated the efficacy of COX-2 inhibition using me-
loxicam; a nonsteroidal anti-inflammatory drug (NSAID) which inhibits
COX-2, in combination with chemotherapy and surgery. The study in-
volving 23 cats, showed no increase in their survival when treated with
this NSAID and a chemotherapeutic combination. However, the dosage,
dosing schedule and toxicity for meloxicam use, are not yet known, and
it is possible that the dose used in this study was inadequate to inhibit
COX-2 to a significant therapeutic level.
3.4. Clinical Trials and the Unmet Clinical Need
As discussed previously, spontaneously occurring FMAs affect a
substantial number of cats globally each year [95]. Similar to humans,
the aggressive phenotype and the propensity to metastasise, makes
these tumours particularly difficult to treat resulting in a poor prog-
nosis.Longstanding evidence exists to suggest that the lack of ER ex-
pression in cats may be suitable for evaluating therapeutic regimens for
breast cancers that are not amenable to hormone targeting approaches
[45]. It is also clear that, despite best efforts to treat felines using ad-
juvant chemotherapy in conjunction with surgery, OS remains con-
sistently low. The finding of new more efficacious therapies is therefore
a clinical priority and unmet clinical need. Despite extensive gene
expression analysis in humans, there has been little analysis carried out
on felines in this area. When cancer related genes; TP53, CCND1, FUS,
YBX1, PTB1, c-myc and PXM2 were initially investigated there was
little known about their function in feline mammary carcinomas [106].
Upon gene expression analysis of 27 mammary malignant tumours
taken from female cats, it was shown that cancer related genes are
associated but may also influence other genes directly. These genes
show a complex cancer network which may in the future provide new
molecular biomarkers [106]. Recent studies have also begun to in-
vestigate the roles of cytokines in feline breast cancer, in particular
CXCR4 and its ligand CXCL12 [118]. Despite being extensively studied
in human breast cancer, the importance of these cytokines was un-
known in feline breast cancer. Analysis of mammary tumours from 115
felines showed that a complex interaction within the CXCR4/CXCL12
axis plays a substantial role in metastasis of breast cancer in cats.
Therefore, Marques et al., also pointed to the potential importance of
these cytokines in targeted therapy for the treatment of mammary
cancer. Although promising, more specific work is needed to
distinguish the exact relevance of CXCR4 and CXCL12 in each clin-
icopathological subtype of feline mammary cancer to predict novel
therapeutic strategies in felines.
Immune profiling has provided revolutionary breakthroughs in the
human cancer arena, however little investigations have taken place in
veterinary patients. A study by Urbano et al., [133] investigated the
levels of CTLA-4, TNFα, IL-6 in the serum of 57 female cats with a
diagnosis of mammary cancer. It was found that increased CTLA-4 was
associated with a “normal” or non “basal-like” status. Additionally,
increased levels was also an indicator of smaller tumour size and overall
better prognosis. The levels of CTLA-4 was attributed to the crosstalk
between the immune cells and tumour microenvironment. Serum
CTLA-4 levels were also positively correlated with serum TNFα and IL-6
levels [133]. Along the same line, a recent work by Nascimento et al.,
[122] has investigated the roles of serum programmed cell death pro-
tein-1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1). It
was shown that levels of these proteins are significantly higher in cats
with a diagnosis of “basal-like” mammary cancer. Recently, a PD-L1
inhibitor which promotes immune suppression has been approved by
the FDA for use in human breast cancer, suggesting the potential for
development of monoclonal antibodies as a therapeutic strategy for the
treatment of “basal-like” breast cancer in feline patients also[122].
Additional work is clearly needed to establish the true effect of the
immune landscape on feline mammary cancers, their development as
novel biomarkers and to establish the potential role of novel im-
munotherapies in these patients.
While clinical trials are somewhat limited for cats, studies in-
vestigating the potential anti-cancer effects of virotherapy have been
reported. Novel investigations into the MG1 strain of the Maraba ver-
iculovirus, have shown potential as an anti-cancer vaccine in FMCs.
Following preclinical research, five pet cats were enrolled to investigate
the safety of the vaccine as a therapeutic [49]. Translational studies in
cats suggested the tolerability and non-pathogenicity of the therapy,
therefore displaying their potential use as a therapy for feline patients.
3.5. Canine BC in Comparison to Feline BC
CMT represent the most common neoplasm of intact adult female
dogs with approximately 50% of these tumours being classified as
malignant [115,121,126]. Certain subtypes have been reported to be
highly metastatic such as anaplastic carcinomas, solid carcinomas and
comedocarcinomas [124]. Few studies have classified CMTs based on
the molecular characterisations of human breast cancers. However,
most of these studies indicate the occurrence of ‘triple negative’ and
basal-like’ subtypes which are associated with poor prognosis [38,115].
In one of these studies carried out by Gama et al.,[38] malignant CMTs
Table 1
Characteristics of human TNBC, FMA in domestic cats and CMT in domestic dogs, illustrating similarities and differences between subspecies.
Human Domestic Cat Domestic Dog
Incidence TNBC accounts for 10–15% of breast cancer
diagnoses
“Basal-like” breast cancer accounts for approximately
79% of all breast cancer diagnoses
“Basal-like” breast cancer accounts for approximately
16% of all breast cancer diagnoses
Humans are genetically diverse Felines are genetically diverse Canines are genetically diverse
Classification Large proportion of TNBC are considered “basal-
like”
Large proportion of FMA are considered “basal-like” Small proportion of CMTs are considered “basal-like”
“Basal-like” expresses CK5/6, Ki-67 and EGFR “Basal-like” expresses CK5/6, Ki-67 and EGFR “Basal-like” expresses CK5, p63 and P-cadherin
Elston and Ellis grading system commonly used Modified Elston and Ellis grading system commonly
used
No optimised grading system available
Metastasis Highly metastatic Highly metastatic Highly metastatic
Metastasis to lung, liver and brain Metastasis to lung, liver and brain Metastasis to lungs and lymph nodes
Treatment Respond slowly to treatments Compressed Pathology; respond quickly to treatments Compressed Pathology; respond quickly to treatments
Standard care is combination chemotherapy in
the adjuvant or neoadjuvant setting
Standard care is surgery, chemotherapies have been
used
Standard care is surgery, chemotherapies have been
use
Clinical trials underway to investigate effects of
COTI-2 on mutant p53
Little daata avaliuable n LiLittle data available on
clinical trials for the treatment of FMA
Little data available on clinical trials for the treatment
of CMT
([2], [15], [14], [19], [24], [35], [36], [52], [54], [55], [49], [59], [61], [63], [66], [91], [97], [101]).
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were characterised based on the phenotypic classification of human
breast cancer, using a panel of six markers (ER, PR, HER2, CK5, p63 and
P-cadherin), which allowed for the identification of four molecular
phenotypes; luminal A, luminal B, HER2-overexpressed, and “basal-
like”. The “basal-like” sub-phenotype was characterised by a high grade
and high proliferation rate, as well as positive expression for cytoker-
atin 5 (CK5), p63 and P-cadherin. This subtype was also associated with
a shorter disease free survival time and overall survival. However, the
incidence of “basal-like” metastatic disease in canines was shown to be
relatively low. In a study by Kim et al., [115] they examined 241 ca-
nines diagnosed with canine mammary carcinoma. Of these 241 tu-
mours, 45 cases (18.7%) were considered triple negative with 34 out of
the 45 considered “basal-like”. Based on this studies, one might suggest
that “triple negative” or “basal-like” breast cancer accounts for a very
small proportion of all canine breast cancers (Table 1). It is however
important to bear in mind that the incidence of metastasis and prog-
nosis is very difficult to predict in the dog, as there are very few large
scale studies of CMT [115].
Histological grading of CMT has also been shown to be a prognostic
indicator. Several grading systems are used with modifications of the
numeric method of Ellston and Ellis being the most common [111,132].
Zapulli et al., [102] reported that age-adjusted overall cancer incidence
per 100,000 individuals per year is comparable in humans and do-
mestic animals with 300 in humans, 381 in dogs and 264 in cats,
however based on canine studies and feline studies discussed in this
review, it is clear that the domestic cat represents a more superior
opportunity to study human breast cancer, in particular TNBC
(Table 1). Another study in support of this statement, was carried out by
Caliari et al., [19] Specifically, they examined tumours from 81 cats
with FMA. Of the 81 cats examined, 93% were malignant tumour
presentations. When this same ratio is calculated in canine patients, it is
clear, that a much larger proportion of cats develop malignant breast
cancers compared to canines. In addition, Caliari et al., [19] reported
that the majority of malignant feline tumours appear phenotypically
similar to TNBCs. This contrasts with studies of malignant canine tu-
mours, where a very small percentage (24%) display the “basal-like”
phenotype. To summarise, as seen in Table 1, it has been found that the
majority of malignant feline mammary carcinomas display a similar
phenotype to human TNBC, therefore potentially representing an
available comparative cohort to study both human and feline TNBC.
Comparative studies of clinical and pathological features of TNBC and
FMA would increase our knowledge of cancer pathogenesis and may
result in the finding of novel targeted therapies in both felines and
humans [102,113,114,135].
Despite the clear benefits of comparative studies, substantial chal-
lenges also exist, particularly in using the cat as a comparative model.
Clinical trials involving the domestic cat are extremely scarce in the
literature [130]. However, it is unclear whether this is due to lack of
resources or lack of knowledge of the population at risk. While LeBlanc,
Mazeka and Khanna [116] proposed that the value of comparative
oncology lies in the critical drug development questions that cannot be
answered by human trials, or conventional preclinical modes, it has also
been noted that the field has mainly focused on tumour bearing dogs.
This may represent the majority of what presents to vets or may also be
due to the fact that the understanding of genetic changes and me-
chanisms resulting in canine cancers are much greater than in cats
[130]. For example, the complete feline genome became available in
2007 [123], while the canine genome had been available since 2005
[131].
It is also impossible to ignore the fact that larger numbers of humans
with breast cancer decide to take part in scientific research.
Incorporation of human breast cancer patients into scientific studies
typically include a large proportion of the breast cancer patients that
have been diagnosed. This is not the case for the feline cohort, as the
selection criteria are often subjective, and the population at risk are not
well known [130]. When subjective criteria are used, all of the cases of
FMA in the population are not diagnosed. This issue may induce se-
lection and diagnostic biases in cats with mammary cancers. Additional
challenges such as a lack of funding for comparative research, is also a
substantial challenge facing researchers as human cancer research or-
ganisations tend to be incognizant to comparative oncology [130].
There can also be challenges with enrolment and engagement with pet
owners. When cat owners were asked whether they would consider
enrolling their pet cat in a clinical trial, many were found to be unsure
[112]. This however represents opportunities at the educational level to
improve recruitment and awareness of the importance of comparative
oncology.
4. Extracellular Vesicles (EVs) and Exosomes
4.1. What are Exosomes?
Extracellular vesicles (EVs), including exosomes, microvesicles,
oncosomes and microparticles, are nanoparticles found in all biological
fluids examined to date [57]. EVs are typically composed of a lipid
bilayer formed from the plasma membrane, which encases genetic
material, proteins and lipids [57]. First described over thirty years ago
[51], these EVs are fundamental in cell-cell communication and the
transmission of disease states [34]. Since its discovery, the term exo-
some has been used loosely to describe an array of EVs. However,
exosomes are best described as “extracellular vesicles that are released
from cells upon fusion of an intermediate endocytic compartment, the mul-
tivesicular body, with the plasma membrane” [34]. Typically between 50
and 150 nm in size, exosomes characteristically display CD63, CD9 and
CD81 tetraspanin proteins [100]. Exosomes may also carry major his-
tocompatibility complex (MHC) class II and heat shock proteins as well
as ALIX and TSG101 [5].
In addition to intracellular communication, recent studies have
demonstrated that exosomes may play an important role as vectors for
drug delivery. An early study by Raposo et al. [82], showed that exo-
somes are capable of carrying the MHC-peptide complexes that can be
recognised by T-lymphocytes to promote antitumor immune responses
in vivo. Exosomes are highly representative of their cells of origin, as
they contain DNA, RNA, proteins, lipids and other molecular con-
stituents of the cell from which they have been released. Exosomes have
also been associated with propagating anti-cancer drug resistance and
the development of metastasis [64]. Upon the discovery of exosomes,
their role in science was largely ignored as they were deemed “waste
containing vehicles” or “a means of cellular disposal”. However recent
analyses have reported a ten-fold increase in publications involving
exosomes [34], identifying their fundamental importance in normal
physiology and pathophysiology [41].
4.2. The role of exosomes in TNBC Metastasis and Disease Progression PPrP
Incremental exosome research has shown that exosomes are also
implicated in the pathogenesis of disease, including TNBC. Extracellular
vesicles are key players of intercellular communication. The more ac-
tive release of exosomes by cancer cells has been acknowledged as a
general cancer trait [89]. However, it is not clear whether exosomes
may be playing a role in TNBC metastasis [27,89]. Research by O'Brien
et al. [72], investigated the capabilities of exosomes to transfer phe-
notypic traits that are representative of their cells of origin to recipient
cells, potentially contributing to the development of distant metastasis.
The results showed that in TNBC, communication via exosomes may
confer aggressive behaviour to secondary recipient cells. It was also
noted by O'Brien et al. [72] that future studies focused on identifying
the specific molecules involved in proliferation (by profiling the con-
tents of these exosomes) and including analyses of larger cohorts of
serum specimens was warranted to expand our understanding of the
functional relevance of exosomes in TNBC. A further study by Ozawa
et al. [74] investigated the role and mechanisms of EVs derived from
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TNBC cells in modulating proliferation and cytotoxicity to non-tu-
mourigenic breast cells. Their study showed that EVs isolated from
TNBC cells were indeed capable of inducing proliferation in non-tu-
mourigenic breast cells. This functional change seen in recipient cells
may be due to changes in genes and miRNAs expression causing them to
proliferate, under apoptosis, invasion other tissues and migrate to other
sites [74].
Despite the clear lack of research and investigation of exosomes in
domestic cats, recent studies have shown that exosomes can be suc-
cessfully isolated from the serum of dogs, cats and horses [119]. Similar
to humans, when exosomes of veterinary patients were profiled in order
to detect whole transferrin receptor in an effort to detect iron defi-
ciency, heterogeneity of relevant markers, soluable transferrin receptor
and cytoplasmic domain was reported between individuals of the same
species [119]. This shows that it is possible to profile exosomes from the
serum of veterinary patients. It was previously proven by Lawson et al.
[57], that extracellular vesicles could be detected in bodily fluids from
mammalian and non-mammalian laboratory species, using non-staining
techniques such as nanoparticle tracking analyses (NTA) and flow cy-
tometry. They also showed that EVs from equine and feline plasma
contain a lipid bilayer, as well as cargo such as genetic material in-
cluding DNA and RNA, proteins and lipids [57]. Their study concluded
that exosome research is providing new insights into how cells com-
municate within different species, showing great potential as bio-
markers for different diseases including cancers in both human and
veterinary patients. Understanding more about the role of EVs in feline
diseases including cancer, may enable the development of a new gen-
eration of diagnostic and prognostic tools for use in the veterinary
clinic. Lawson et al. [57] stated that “development of assays to measure
EVs from veterinary species will enable high quality care and enhanced
welfare of patients”.
However, some research has been carried out in canines that sug-
gests that the profiling of EVs from domestic cats may yield some in-
teresting results. Fish et al., [109] showed that breast cancers from cell
lines shed exosomes that contain microRNAs into the tumour micro-
environment and circulation, therefore potentially representing bio-
markers of metastasis and tumour phenotype. When exosomes from
culture media from CMT derived cell lines were compared to exosomes
from non-cancerous cells, it was found that certain microRNAs are
upregulated in the exosomes secreted from tumour cells. These micro-
RNAs are predicted to target biologically relevant hormone receptors
and oncogenic pathways [109]. This extremely revolutionary study in
the area of exosomes and veterinary medicine may only represent the
tip of the iceberg for these nanoparticles. Therefore, in relation to TNBC
and FMA, a comparative approach to exosomal profiling may provide
the key to unravelling the molecular complexity and aggressiveness of
TNBC which may lead to changes or improved treatments for both fe-
line and human populations.
4.3. Exosomes and Chemoresistance C
Chemoresistance refers to the resilience of the cancer cells to avoid
apoptosis-induced death by a chemotherapeutic agent. The widely ac-
cepted mechanism of chemoresistance involves changes in the tumour
microenvironment, which is hypothesised to depend heavily on exo-
somes. MicroRNAs (miRNAs) are known to play a role in the formation
of cancer stem cells and subsequent Epithelial-to-Mesenchymal
Transition (EMT), forming hallmarks of breast cancer [83]. Interest-
ingly, there is increasing evidence that EVs might have a role in che-
moresistance. In 2018, a study looked at the significance of miRNA-155
in mediating chemoresistance in breast cancer cells, with the potential
for the development of miRNA-155 as a therapeutic target. The study
showed that, exosomes are capable of binding to neighbouring cells and
modifying recipient cell phenotypes on uptake; the miRNA carried by
exosomes is translated into recipient cells, potentially mediating these
changes. Upon further analysis of the role of the microRNA-155 in
chemoresistance, it was shown that cells that received exosomes that
had high levels of miR-155, were significantly more resistant to che-
motherapeutic agents such as doxorubicin and paclitaxel [83]. A role of
exosomes in TNBC chemoresistance has been confirmed by Ozawa et al.
[74], where studies showed that extracellular vesicles from TNBC cells
are capable of inducing chemoresistance in normal non-cancerous
breast epithelial cells.
Although the role of exosomes in mediating chemoresistance in fe-
line patients has not been investigated in as much detail, exosome de-
rived microRNAs have been shown to be significantly associated with
the progression of renal dysfunction in felines [50], demonstrating the
potential role of exosomes in the pathogenesis of disease. Similarly, the
role of miRNAs in cardiomyopathy has recently been investigated [99].
The parallels between human TNBC and FMA support investigation of
the potential of EVs as biomarkers, and mediators of chemoresistance in
veterinary medicine.
5. The FFuture of Comparative Oncology C O
5.1. Liquid Biopsy for Diagnosis B D
A liquid biopsy, also known as a fluid biopsy, refers to the sampling of
non-solid biological tissue, mainly blood in the form of plasma or serum
to inform on some disease state. Altho Although a routine clinical
procedure,the use of these liquid biopsies for the isolation of exosomes
or other particles harbouring pathophysiological information is novel.
Exosomes are cellular reflections of their cells of origin. Therefore, the
use of liquid biopsies in this way has been described as a revolutionary
technique harbouring a wealth of undiscovered genetic information. A
study by Stover et al. [90], demonstrated the potential impact of the
liquid biopsy for humans in the cancer diagnostic setting. Their study
showed that metastatic TNBC could be characterised based on the Cell-
Free DNA (cfDNA), harvested from the blood samples of 164 patients
whereg genomic characterisation of the metastatic TNBC was carried
out exclusively on the cfDNA alone. It was demonstrated that in-
formation regarding metastasis and chemoresistance could be obtained
using this liquid biopsy approach and further demonstrated a novel
aspect of breast cancer profiling as well as the power of the liquid
biopsy in the clinical setting [90].Similar to humans, liquid biopsy
samples from domestic cats also present the opportunity to characterise
cfDNA of feline mammary adenocarcinoma. A study by Leal et al.,
[117]used cfDNA to detect residual disease in felines with gastric
cancer. They were able to identify patients who had benefitted from
perioperative gastric cancer treatment [117]. It can therefore be de-
duced that a similar approach to monitoring disease progression in
feline mammary adenocarcinoma has huge potential in the clinical
setting. As with humans, exosomes isolated from the blood of felines
with mammary cancer has the potential to inform on disease progres-
sion and prognosis. EVs have been isolated, identified and characterised
from felines with a diagnosis of mammary cancer [125]. It was con-
cluded that the preliminary study which identified and characterised
EVs from felines with mammary tumours represents a new interesting
field with several applications and limitless potential [125]. Harvested
exosomes therefore have the potential to inform on the location of
metastasis and resistance to chemotherapy in the clinical setting in both
human and veterinary medicine.
5.2. Conclusion: A Comparative Oncology Approach
The poor prognosis, lack of specialised or effective treatment regi-
mens and susceptibility to the development of metastasis of TNBC is the
epitome of an unmet clinical need. Like TNBC, FMAs are similar to
human “basal-like” breast cancer (a subset of TNBC). They too carry a
poor prognosis, and also lack efficacious treatments. Felines typically
display a compressed pathology compared to humans. Therefore,
changes in their disease, such as in response to new treatments may be
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seen more quickly thus supporting the comparative oncology approach.
Comparative oncology may reveal novel information that could not be
inferred from rodent models, and cats with FMA can contribute to and
benefit from TNBC research. As such, this is in keeping with the defi-
nition of comparative oncology; to benefit both humans and animals
equally.
A wealth of exosome research has occurred in recent years, which
has been particularly interesting for TNBC researchers and patients
alike. The potential roles of exosomes in TNBC metastasis and che-
moresistance warrants further investigation which may unlock their
true potential as biomarkers. In a collaborative environment, exosomes
may be harvested from liquid biopsies of both humans and felines to
potentially unravel the complex characteristics of both triple negative
breast cancer and feline mammary adenocarcinoma to the potential
greater good and care of both.
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